Events
The Association of Breast Pathology (ABP) and the British Division of the International Academy of Pathology (BDIAP)
Join the APIS team at ABP x BDIAP 2024
The Association of Breast Pathology (ABP) and the British Division of the International Academy of Pathology (BDIAP) will be holding a joint meeting this year on Friday 22 November and Saturday 23 November 2024 at the Royal Society of Medicine, 1 Wimpole Street, London.
Come and meet the APIS team to discover the:
The APIS Breast Cancer Subtyping Kit is a highly reproducible, RT-qPCR based IVD product (in certain territories) and RUO product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers. This assay can help direct clinicians to the right treatment more quickly with higher accuracy.
The APIS ESR1 qPCR Kit is an advanced qPCR assay for the sensitive and precise detection of mutations within the estrogen receptor gene. The Kit is a qualitative test, detecting eleven ESR1 mutations across exons 5 (E380Q), 7 (S463P) and 8 (P535H, L536R, L536Q, L536H, L536P, Y537C, Y537S, Y537N and D538G).
The new APIS PIK3CA qPCR Kit is a real-time qualitative PCR test for the detection of the five most prevalent activating mutations in the PIK3CA gene, using a sample of DNA extracted from either formalin-fixed, paraffin-embedded (FFPE) breast tumour tissue or blood plasma (cfDNA).
The APIS MET Alterations Kit is a RT-qPCR assay detecting both MET exon 14 skipping mutation and MET gene overexpression.
The new ESR1 dPCR Kit is a dPCR assay detecting 11 key mutations within the oestrogen receptor gene.
Use this link to contact us and schedule a meeting.
APIS goes to AMP 2024!
Come and meet the APIS team to discover the:
The APIS Breast Cancer Subtyping Kit is a highly reproducible, RT-qPCR based IVD product (in certain territories) and RUO product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers. This assay can help direct clinicians to the right treatment more quickly with higher accuracy.
The APIS ESR1 qPCR Kit is an advanced qPCR assay for the sensitive and precise detection of mutations within the estrogen receptor gene. The Kit is a qualitative test, detecting eleven ESR1 mutations across exons 5 (E380Q), 7 (S463P) and 8 (P535H, L536R, L536Q, L536H, L536P, Y537C, Y537S, Y537N and D538G).
The new APIS PIK3CA qPCR Kit is a real-time qualitative PCR test for the detection of the five most prevalent activating mutations in the PIK3CA gene, using a sample of DNA extracted from either formalin-fixed, paraffin-embedded (FFPE) breast tumour tissue or blood plasma (cfDNA).
The APIS MET Alterations Kit is a RT-qPCR assay detecting both MET exon 14 skipping mutation and MET gene overexpression.
The new ESR1 dPCR Kit is a dPCR assay detecting 11 key mutations within the oestrogen receptor gene.
Use this link to contact us and schedule a meeting.
Don’t miss our poster sessions on:
Session: Solid Tumors
Date: Friday, November 22nd
Time: 9:15am – 10:15am Pacific
Session: Solid Tumors
Date: Saturday, November 23rd
Time: 9:15am – 10:15am Pacific
Session: Solid Tumors
Date: Saturday, November 23rd
Time: 9:15am – 10:15am Pacific
Session: Solid Tumors
Date: Saturday, November 23rd
Time: 9:15am – 10:15am Pacific
International Annual Meeting on Breakthroughs in breast cancer research and treatment
BBC Annual Meeting 2024
Come and meet the APIS team to discover the:
The APIS Breast Cancer Subtyping Kit is a highly reproducible, RT-qPCR based IVD product (in certain territories) and RUO product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers. This assay can help direct clinicians to the right treatment more quickly with higher accuracy.
The APIS ESR1 Mutations Kit is an advanced qPCR assay for the sensitive and precise detection of mutations within the estrogen receptor gene. The Kit is a qualitative test, detecting eleven ESR1 mutations across exons 5 (E380Q), 7 (S463P) and 8 (P535H, L536R, L536Q, L536H, L536P, Y537C, Y537S, Y537N and D538G).
The new APIS PIK3CA Mutations Kit is a real-time qualitative PCR test for the detection of the five most prevalent activating mutations in the PIK3CA gene, using a sample of DNA extracted from either formalin-fixed, paraffin-embedded (FFPE) breast tumour tissue or blood plasma (cfDNA).
The APIS MET Alterations Kit is a RT-qPCR assay detecting both MET exon 14 skipping mutation and MET gene overexpression.
The new ESR1 dPCR Kit is a dPCR assay detecting 11 key mutations within the oestrogen receptor gene.
Use this link to contact us and schedule a meeting.
8th World Congress on Controversies in Breast Cancer
Don’t miss the APIS team at the 8th World Congress on Controversies in Breast Cancer
Come and meet the APIS team at booth #7 to discover the:
The APIS Breast Cancer Subtyping Kit is a highly reproducible, RT-qPCR based IVD product (in certain territories) and RUO product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers. This assay can help direct clinicians to the right treatment more quickly with higher accuracy.
The APIS ESR1 Mutations Kit is an advanced qPCR assay for the sensitive and precise detection of mutations within the estrogen receptor gene. The Kit is a qualitative test, detecting eleven ESR1 mutations across exons 5 (E380Q), 7 (S463P) and 8 (P535H, L536R, L536Q, L536H, L536P, Y537C, Y537S, Y537N and D538G).
The new APIS PIK3CA Mutations Kit is a real-time qualitative PCR test for the detection of the five most prevalent activating mutations in the PIK3CA gene, using a sample of DNA extracted from either formalin-fixed, paraffin-embedded (FFPE) breast tumour tissue or blood plasma (cfDNA).
Use this link to contact us and schedule a meeting.
European Congress of Pathology 2024
The APIS team are excited to be exhibiting at the European Congress of Pathology!
Come and meet us at booth #120 to learn about:
· APIS Breast Cancer Subtyping Kit
· APIS ESR1 Mutations Kit
· APIS PIK3CA Mutations Kit
· APIS MET Alterations Kit
& our new PGx Assays!
Don’t miss our poster sessions on:
Session: Poster Session Breast Pathology and Best Poster Sessions
Date: 08/09/2024
Time: 09:30 - 10:30 and 16:45 - 17:15
2. Measuring ESR1 mutations in liquid biopsy and FFPE breast tissue using qPCR
Session: Poster Session Breast Pathology
Date: 08/09/2024
Time: 09:30 - 10:30
Poster number: 015
Session: Poster Session Breast Pathology
Date: 08/09/2024
Time: 09:30 - 10:30
Poster number: 013
No poster session - available as PDF.
Use this link to contact us and schedule a meeting.
We look forward to seeing you in Florence!
From Data to Insights: Interactive Visualisation for Target Discovery
Join us for an educational webinar session as we delve into the fascinating world of interactive visualisations to interpret complex data generated in target validation process with APIS Target Triage pipeline.
Novak Martinovic from APIS Assay Technologies will share his expertise and insights into this challenging field.
Webinar Highlights:
Enhancing Complex Data Interpretation:
Learn how to make sense of complex data sets using interactive visualisations. Discover techniques that help you gain more accurate and insightful results.Practical Demonstrations:
Watch real-world examples of powerful visualisation tools in action. See how these methods are used specifically to aid in finding targets during drug discovery.Integration Strategies:
Get essential tips and best practices for incorporating interactive visualisations into your research workflow. Improve your efficiency and effectiveness in discovering drug targets.
Don’t miss the opportunity to gain practical knowledge and network with fellow experts in the field.
Register now 👉🚀https://attendee.gotowebinar.com/register/6603149406283876960?source=APIS+Website
Want to learn more? Book a meeting with us to discuss 👉https://bit.ly/ApisBioinformatics
Understanding HER2 Expression in Breast Cancer: The Emerging Role of HER2-Low
Join us for an educational webinar session where we explore the relevance of HER2 expression in invasive breast cancer.
Our presenters, Anna Gasior and Leanne Gough from APIS Assay Technologies, will provide a comprehensive overview of the latest advancements in HER2 expression testing, with a particular emphasis on the emerging concept of HER2-low.
Webinar Highlights:
HER2 as a predictive and prognostic marker in invasive breast cancer
HER2 testing methodologies
The significance of HER2-low classification
Implications for treatment strategies
Have your questions answered by experts in gene mutation assay development and validation!
Register here: https://attendee.gotowebinar.com/register/3150349743017902679?source=APIS+Website
APIS goes to Sheffield Pathology 2024
Don’t miss the APIS team at Sheffield Pathology 2024!
Come and chat to us and discuss:
The APIS Breast Cancer Subtyping Kit is a highly reproducible, RT-qPCR based IVD product (in certain territories) and RUO product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers. This assay can help direct clinicians to the right treatment more quickly with higher accuracy.
The APIS ESR1 Mutations Kit is an advanced qPCR assay for the sensitive and precise detection of mutations within the estrogen receptor gene. The Kit is a qualitative test, detecting eleven ESR1 mutations across exons 5 (E380Q), 7 (S463P) and 8 (P535H, L536R, L536Q, L536H, L536P, Y537C, Y537S, Y537N and D538G).
The new APIS PIK3CA Mutations Kit is a real-time qualitative PCR test for the detection of the five most prevalent activating mutations in the PIK3CA gene, using a sample of DNA extracted from either formalin-fixed, paraffin-embedded (FFPE) breast tumour tissue or blood plasma (cfDNA).
Use this link to contact us and schedule a meeting.
APIS will be attending ESMO Breast Cancer 2024!
Don’t miss the APIS team attending ESMO Breast at booth 27!
Come and chat to us to discuss:
The APIS Breast Cancer Subtyping Kit is a highly reproducible, RT-qPCR based IVD product (in certain territories) and RUO product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers. This assay can help direct clinicians to the right treatment more quickly with higher accuracy.
The APIS ESR1 Mutations Kit is an advanced qPCR assay for the sensitive and precise detection of mutations within the estrogen receptor gene. The Kit is a qualitative test, detecting eleven ESR1 mutations across exons 5 (E380Q), 7 (S463P) and 8 (P535H, L536R, L536Q, L536H, L536P, Y537C, Y537S, Y537N and D538G).
The new APIS PIK3CA Mutations Kit is a real-time qualitative PCR test for the detection of the five most prevalent activating mutations in the PIK3CA gene, using a sample of DNA extracted from either formalin-fixed, paraffin-embedded (FFPE) breast tumour tissue or blood plasma (cfDNA).
Use this link to contact us and schedule a meeting.
Don't miss the APIS team at ABS conference 2024!
APIS will be exhibiting at The Association of Breast Surgery 2024!
Don’t miss the team at booth 42 to discuss:
The APIS Breast Cancer Subtyping Kit is a highly reproducible, RT-qPCR based IVD product (in certain territories) and RUO product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers. This assay can help direct clinicians to the right treatment more quickly with higher accuracy.
The APIS ESR1 Mutations Kit is an advanced qPCR assay for the sensitive and precise detection of mutations within the estrogen receptor gene. The Kit is a qualitative test, detecting eleven ESR1 mutations across exons 5 (E380Q), 7 (S463P) and 8 (P535H, L536R, L536Q, L536H, L536P, Y537C, Y537S, Y537N and D538G).
The new APIS PIK3CA Mutations Kit is a real-time qualitative PCR test for the detection of the five most prevalent activating mutations in the PIK3CA gene, using a sample of DNA extracted from either formalin-fixed, paraffin-embedded (FFPE) breast tumour tissue or blood plasma (cfDNA).
Use this link to contact us and schedule a meeting.
APIS goes ECCMID 2024!
Don’t miss APIS at ECCMID 27th April, 2024
Come and meet our team of expertise at booth F32
It’s a perfect chance to discuss:
· Contract assay development opportunities
· Clinical Compliance Services
· Clickmers
· Infectious disease and microbiology capabilities
Interested? Contact us to arrange a meeting: Contact — APIS Assay Technologies Ltd
APIS goes to BioIT-World Conference & Expo
Heading to BioIT-World Conference in Boston 15-17 April?
So is our Head of Bioinformatics, Aleksandar Mihajlovic
It’s a perfect chance to discuss:
· Opportunities in AI & ML for biomarker and drug discovery
· Algorithm and bioinformatics pipeline development and evidence extrapolation from data
· Bioinformatics cloud platforms development
Interested? Schedule a call with us via our booking link: https://bit.ly/ApisBioinformatics
Streamlining Biomarker Discovery: From Theory to Application
🌟 Webinar Alert! 🌟
Streamlining Biomarker Discovery: From Theory to Application
Join us for an educational webinar session as we delve into the fascinating world of biomarker discovery and its crucial role in Breast Cancer Subtyping. Our presenters Svetozar Nesić and Marko Tumbas from APIS Assay Technologies, will guide you through the complexities of this cutting-edge field.
🔍 Webinar Highlights:
Biomarker selection
Designing a biomarker signature
Develop a predictive algorithm capable of addressing the high dimensionality of biological datasets
Determine the minimal marker subset capable of achieving the desired predictive power
Translate findings obtained using data to train ML models and test obtained signature robustness
📅 Date: 11th April 2024 ⏰ Time: 14:00 (BST)
Don’t miss this opportunity to gain practical knowledge and network with fellow enthusiasts. Register now 🚀 https://attendee.gotowebinar.com/register/2901291665925058903?source=APIS+Website
Want to learn more? Book a meeting with us to discuss 👉 https://bit.ly/ApisBioinformatics
ESR1 Mutations as Essential Markers for Understanding Endocrine Therapy Resistance
Oestrogen receptor 1 (ER/ESR1) mutations have arisen as crucial biomarkers for endocrine therapy resistance in ER positive metastatic breast cancer. Detecting these mutations is key for understanding acquired resistance during treatment.
APIS will be joined by SensID GmbH to deliver this FREE educational webinar on ESR1 mutations and the importance of their accurate and sensitive detection.
Gain insights into:
- ESR1 mutations significance in breast cancer and their role in endocrine therapy resistance
- APIS ESR1 Mutations Kit, an accessible method to detect ESR1 mutations
- SensID ESR1 reference set to ensure accurate detection of mutations in cell-free DNA (cfDNA)
Have your questions answered by experts in gene mutation assay development and validation!
Register here: https://attendee.gotowebinar.com/register/8248345354064775003?source=APIS+Website
Clickmers® webinar
Join us for our educational webinar on ‘Clickmers® as a Powerful Tool in a Rapidly Changing Pathogen Landscape’.
Clickmers are versatile DNA-based detection molecules that can be used in various types of assays ranging from diagnostics to therapeutics.
Gain insights into:
The fundamentals of Clickmers, their role, and significance in therapeutics and diagnostics
How Clickmers unique properties enable faster responses to emerging pathogens
How Clickmers can differentiate between tick-borne encephalitis (TBEV) NS1 and other highly similar flavivirus NS1 protein
We hope you can join us on: Thursday 15th February, 14:00-15:00 (GMT)
Register to secure your spot: https://attendee.gotowebinar.com/register/6764377390145455196?source=APIS+LinkedIn
BioX Webinar Ep.3
Join us for the third episode of our educational webinars, this time on "Navigating the Future of Drug Discovery: Public Data & AI in Target Discovery"
During this session, Aleksandar Mihajlovic and Aleksandra Gulbicka (APIS Assay Technologies Ltd.) will guide you through the realm of drug discovery, exploring the synergistic integration of public data and AI.
Don’t miss gaining valuable insights into:
· Setting the Stage for Innovation: Discover how the convergence of public data and AI is reshaping the landscape of pharmaceutical research
· Modifying Questions for Biomarkers: Explore novel strategies for adapting biomarker-related questions in drug discovery research
· Clickmers: Uncover the fundamentals of Clickmers, their role, and significance in modern drug discovery
We hope you can join us on: Thu 14th December, 14:00-15:00 (GMT)
Register to secure your spot 👉 https://bit.ly/3RboQfS
Precision Oncology Europe
Dont miss APIS presenting at Precision Oncology Europe - ‘Advantages of Using Clickmer Technology for the Detection of Biomarkers’
Dr. Nora Karnowski’s presentation will outline the advantages of Clickmer technology and how they can support biomarker development:
Clickmers are modified DNA aptamers that bind to their biomarker targets with nanomolar affinity. They can be developed within weeks, have high specificity and can be quantified using enzymatic, fluorescent, or qPCR readout for improved sensitivity.
The APIS Breast Cancer Subtyping Kit is a highly reproducible, RT-qPCR based IVD product (in certain territories) and RUO product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers.
The APIS ESR1 Mutations Kit is an advanced qPCR assay for the sensitive and precise detection of mutations within the oestrogen receptor gene. The kit has a wide target coverage of 11 different ESR1 mutations.
Use this link to contact us and schedule a meeting.
AMP 2023
Join the APIS team at AMP 2023
APIS is leveraging systems biology, interrogating multi-OMICs biodata, and deploying ‘Clickmer’ ligand binding technology, for the validation and translation of biomarker and therapeutics into clinical utility.
Find out about our expertise and capabilities in IVD development of molecular & immune-assays for product realisation as diagnostic tests. APIS expertise in bioinformatics is offered as an agile service, to develop bespoke, end-to-end multi-OMICs solutions and platform development.
The APIS Breast Cancer Subtyping Kit is a highly reproducible, RT-qPCR based IVD product (in certain territories) and RUO product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers.
The APIS ESR1 Mutations Kit is an advanced qPCR assay for the sensitive and precise detection of mutations within the oestrogen receptor gene. The kit has a wide target coverage of 11 different ESR1 mutations.
Use this link to contact us and schedule a meeting
Decoding the Future: How Cloud Computing is Reshaping Bioinformatics
Join us for the second episode of our educational webinars on "Decoding the Future: How Cloud Computing is Reshaping Bioinformatics".
During this session, presenters Nikola Nonkovic (APIS Assay Technologies) and Victor Weigman (BioSkryb) will guide you through the transformative journey of bioinformatics from its inception in traditional data centers to the expansive possibilities within the cloud.
Webinar highlights:
The Evolution of Bioinformatics: Traverse the journey from data centers to the limitless potential of the cloud.
Cloud Technologies & Bioinformatics: Understand the profound impact of cloud solutions in the realm of bioinformatics, specifically as it applies to single-cell genomic and transcriptomic analysis.
To Build or Not to Build: Delve into the decision-making process behind creating custom bioinformatics applications versus licensed solutions.
We hope you can join us on: Thu 26th October, 15:00-16:00 (GMT)
Register to secure your spot: https://bit.ly/3tkNSRw
APIS are presenting at ACRO Biosystems Symposium
Don’t miss APIS presenting at ACRO Biosystems Symposium - ‘The potential of Clickmers to accelerate the development of safer drugs’
Dr. Nora Karnowski’s presentation will outline how the Clickmer technology can support drug development
Fast discovery, characterisation and assay development to aid e.g. patient stratification
Innovative selection methods to achieve special features such as targeting of undruggables like GPCRs or conditional activation
Register now 👉: https://bit.ly/3FmjusL
BioTechX Europe Conference
Don’t miss the APIS team at BioTechX Europe!
APIS is leveraging systems biology and interrogating multi-OMICs biodata for the validation and translation of biomarker into clinical utility.
Utilising the transformational power of systems biology, innovative synthetic antibody technologies, and genomic big data APIS directly addresses the historical failures of translating biomarkers into clinical utility.
Operating under an ISO 13485 QMS, APIS seeks to develop and manufacture proprietary and client derived disease- and tissue-agnostic biomarkers as IVD tests (MDx, CDx and CoDx), maximising the benefit to both patients and stakeholders in either a centralised or de-centralised laboratory setting.
Use this link to contact us and schedule a meeting.
Nextflow Bioinformatics Pipelines and Workflow Management: A Comprehensive Webinar
Join Srdjan Kasapovic and guest speaker Dr. Harshil Patel (Seqera Labs) for an informative webinar on "Nextflow Bioinformatics Pipelines and Workflow Management".
In this session, we will provide valuable insights into:
Nextflow bioinformatics pipelines
Pipeline design best practices
The difference between open source and commercial pipelines
Nextflow Tower for efficient workflow management
We hope you can join us on:
Tue 19th September, 16:00 PM - 17:00 PM (CEST)
Register here to secure your spot and have your questions answered by our expert presenters!
35th European Congress of Pathology
Join the APIS team at the 35th European Congress of Pathology in Dublin, Ireland.
APIS is leveraging systems biology and interrogating multi-OMICs biodata for the validation and translation of biomarker into clinical utility.
We proudly present:
The APIS Breast Cancer Subtyping Kit, a highly reproducible, RT-qPCR based product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers.
The new APIS ESR1 Mutations Kit, an advanced qPCR assay for the sensitive and precise detection of mutations within the oestrogen receptor gene. The kit has a wide target coverage of 11 different ESR1 mutations.
Use this link to contact us and schedule a meeting.
World Clinical Biomarker & CDx 2023
The APIS team will be exhibiting and presenting at the 13th World Clinical Biomarker & CDx 2023 in Boston.
Be sure not to miss Program Lead, Joanna Gorniak, PhD, presenting on Day 2, Friday 8th September at 4 PM with her talk titled ‘HER2 Stratification with a Novel Diagnostic Test’.
APIS is leveraging the transformational power of systems biology, innovative synthetic antibody technologies, and genomic big data to directly address the historical failures of translating biomarkers into clinical utility.
Operating under an ISO 13485 QMS, APIS seeks to develop and manufacture proprietary and client derived disease- and tissue-agnostic biomarkers as IVD tests (MDx, CDx and CoDx), maximising the benefit to both patients and stakeholders in either a centralised or de-centralised laboratory setting.
Use this link to contact us and schedule a meeting.
AACC Annual Scientific Meeting & Clinical Lab Expo 2023
The APIS team will be exhibiting at AACC Annual Scientific Meeting & Clinical Lab Expo 2023.
Be sure not to miss our team of experts at Booth 2482.
APIS is leveraging systems biology, interrogating multi-OMICs biodata, and deploying ‘Clickmer’ ligand binding technology, for the validation and translation of biomarker and therapeutics into clinical utility.
Find out about our expertise and capabilities in IVD development of molecular & immune-assays for product realisation as diagnostic tests. APIS expertise in bioinformatics is offered as an agile service, to develop bespoke, end-to-end multi-OMICs solutions and platform development.
The APIS Breast Cancer Subtyping Kit (RUO) is a highly reproducible, RT-qPCR based product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers.
The new APIS ESR1 Mutations Kit is a research use only, advanced qPCR assay for the sensitive and precise detection of mutations within the oestrogen receptor gene. The Kit is a qualitative test, detecting eleven ESR1 mutations across exons 5 (E380Q), 7 (S463P) and 8 (P535H, L536R, L536Q, L536H, L536P, Y537C, Y537S, Y537N and D538G).
Use this link to contact us and schedule a meeting.
Liverpool Pathology 2023
Join the APIS Team at Liverpool Pathology 2023 for the 14th Joint Meeting of the British Division of the International Academy of Pathology and the Pathological Society.
27-29th June 2023
APIS is leveraging systems biology, interrogating multi-OMICs biodata, and deploying innovative synthetic ‘Clickmer’ high-affinity ligand binding technology, for the validation and translation of biomarker and drug assets into clinical utility.
APIS has deep expertise and capabilities in platform agnostic IVD development of molecular & immunoassays for ultimate product realisation as IVD tests.
The APIS Breast Cancer Subtyping Kit is a highly reproducible, RT-qPCR based IVD product (in certain territories) and RUO product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers. This assay can help direct clinicians to the right treatment more quickly with higher accuracy.
The new APIS ESR1 Mutations Kit is an advanced qPCR assay for the sensitive and precise detection of mutations within the estrogen receptor gene. The Kit is a qualitative test, detecting eleven ESR1 mutations across exons 5 (E380Q), 7 (S463P) and 8 (P535H, L536R, L536Q, L536H, L536P, Y537C, Y537S, Y537N and D538G).
Interested in learning more? Use this link to contact us and schedule a meeting.
Antibody Engineering & Therapeutics Europe
The APIS team will be exhibiting and speaking at the Antibody Engineering & Therapeutics Europe conference at the Postillion Hotel, Amsterdam.
Come and meet us at stand 21.
APIS’ deep expertise and capabilities in platform agnostic IVD development of molecular & immunoassays for ultimate product realisation as diagnostic tests.
Innovative synthetic ‘Clickmer’ high-affinity ligand binding technology, for the validation and translation of biomarker and drug assets into clinical utility.
The APIS SARS-CoV-2 IgG ELONA Kit is intended for the quantitative detection of IgG antibodies to SARS-CoV-2 spike protein in human serum and utilises Clickmers. The results of this assay will aid in clinical decision making, vaccine development and booster dosing, and clinical research studies.
Interested in learning more? Use this link to contact us and schedule a meeting.
Clickmers Webinar
Join Dr. Maren Hamann and Dr. Nora Karnowski for a must-attend virtual webinar that will introduce the revolutionary Clickmer Systems.
Synthetic affinity reagents known as Clickmers are chemically modified ssDNA oligonucleotides that, based on their sequence and modifications, form three-dimensional structures that adaptively bind to their target molecules with high affinity and specificity.
Clickmers can be used, for example, to detect viral infections, determine vaccination status or detect rejection reactions after organ transplants.
We hope you can join us on:
Tue 9th May, 14:00 PM - 15:00 PM (GMT)
To register follow the link: https://bit.ly/3AhWvwh
13th Clinical Biomarkers & CDx Europe 2023
The APIS Team will be exhibiting and presenting at the 13th Clinical Biomarkers & CDx Europe 2023 in London.
Be sure not to miss our Chief Operating Officer, Ian Kavanagh, presenting on Day 1 at 9:50 AM in the plenary session with his talk titled ‘HER2 Stratification with a Novel Diagnostic Test’.
Discovering the potential of the APIS Breast Cancer Subtyping Kit for faster HER2 result turnaround without the need for reflex testing to ISH
Learning how to significantly reduce time for results interpretation with automatic results via validated software
The detection ability of lowly expressed ERBB2 levels aligns the IVD test as a CDx to HER2 targeted therapies, such as Trastuzumab deruxtecan
Interested in learning more? Use this link to contact us and schedule a meeting.
ECCMID 2023
The APIS Team will be exhibiting at ECCMID 2023 in Copenhagen, Denmark.
APIS Assay Technologies core expertise and capabilities are contract development of molecular & immunoassay assays and their ultimate product realisation as IVD approved assays, and the related clinical compliance services (particularly for CE-IVDR).
Operating under ISO 13485 and supported by the required clinical & compliance teams, we have expertise in developing PCR (RT-qPCR, qPCR, dPCR), NGS and immunoassay (e.g. ELISA & ELONA) IVD tests. Our onsite microbiology facilities provide our clients the capabilities to develop multiplex infectious disease panels in-house.
Our new APIS SARS-CoV-2 IgG ELISA Kit is intended for the quantitative detection of IgG antibodies to SARS-CoV-2 spike protein in human serum. The assays’ results will aid in clinical decision making, vaccine development and booster dosing, disease prevention and research studies.
Interested in learning more? Use this link to contact us and schedule a meeting.